The combination of continued operating losses, severe cash burn, massive shareholder dilution, and a material internal control weakness signals significant financial distress. Monitor the company's ability to raise additional capital or generate positive cash flow, and watch for any Nasdaq delisting risk if the stock price falls below $1.00 again. The securities class action lawsuit adds legal overhang.
Price Chart
Executive Summary
Basel Medical Group Ltd filed its annual report on Form 20-F for FY2026 (ended June 30, 2026). Revenue grew 45.2% to S$16.44M, but the company remained unprofitable with a net loss of S$1.43M (improved from S$10.64M loss in FY2025 which included a S$10.35M goodwill impairment). Cash burn was severe: cash and cash equivalents fell from S$3.04M to S$0.53M, and operating cash flow was negative S$0.64M. The filing confirms massive dilution from the October 2026 registered direct offering (6M new shares issued, plus 6M warrants exercisable at zero cash) and the subsequent warrant exercise (6M additional shares issued with no proceeds), increasing outstanding shares from 1.58M to 13.58M. A securities class action lawsuit was filed in July 2026. The company disclosed a material weakness in internal controls over financial reporting.
Key Facts
- Revenue increased 45.2% to S$16,441,770 (US$12,808,828) for FY2026, from S$11,319,944 in FY2025.
- Net loss improved to S$1,429,395 (US$1,113,559) from S$10,636,178 in FY2025, which included a S$10,349,252 goodwill impairment.
- Cash and cash equivalents declined sharply from S$3,044,466 to S$529,887 (US$409,464).
- Net cash used in operating activities was S$635,207 (US$531,956).
- Total outstanding shares increased from 1,582,111 (post-reverse split) to 13,582,111 after the October 2026 offering and subsequent warrant exercise, representing approximately 758% dilution from the pre-offering count.
- A securities class action lawsuit was filed on July 23, 2026 in New York state court, naming the company among over 30 defendants.
- Management identified a material weakness in internal control over financial reporting due to lack of adequately skilled staff with IFRS knowledge.
- The company's ability to continue as a going concern is dependent on shareholder financial support, generating sustainable profits, and procuring additional financing.
- A 1-for-12 reverse share split was effected on June 22, 2026 to regain Nasdaq minimum bid price compliance.
- The company had negative equity attributable to non-controlling interests of S$520,218 and total equity of S$4,536,327.
Financial Impact
Revenue grew 45.2% to S$16.44M but net loss was S$1.43M. Cash burn of S$2.51M during the year. Massive dilution: shares outstanding increased from 1.58M to 13.58M (758% increase) from the October 2026 offering and subsequent warrant exercise. Cash balance fell to S$0.53M.
Risk Factors
- Going concern risk: cash balance of only S$0.53M with negative operating cash flow and reliance on shareholder support and additional financing.
- Massive dilution: 6M additional shares from warrant exercise and 6M warrants still outstanding with zero-cash exercise option create substantial overhang.
- Nasdaq delisting risk: the company recently regained compliance via a reverse split but the highly dilutive offering could push the stock price below the $1.00 minimum bid again.
- Securities class action lawsuit filed in July 2026 could result in material costs and management distraction.
- Material weakness in internal controls over financial reporting increases risk of financial misstatements.
- Subsidiaries Eyetrust Medical and Pharma Avenue were struck off or in process of being struck off post-year-end, indicating operational contraction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001493152-26-049381 |
| Exhibit: ex8-1.htm | 0001493152-26-049381 |
| Exhibit: ex12-2.htm | 0001493152-26-049381 |
| Exhibit: ex12-1.htm | 0001493152-26-049381 |
| Exhibit: ex13-2.htm | 0001493152-26-049381 |
| Exhibit: ex13-1.htm | 0001493152-26-049381 |
| Document: 0001493152-26-049381-index-headers.html | 0001493152-26-049381 |
| Document: 0001493152-26-049381-index.html | 0001493152-26-049381 |
| Document: 0001493152-26-049381.txt | 0001493152-26-049381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 20-F | $4.99 | awaiting T+1 | awaiting T+1 | $5.04 (−1.10%) |
Oct 29, 2026 3d ago | 6-K | $4.75 $5.04 | ▼ −6.11% | ▼ −7.88% | $5.04 (−6.11%) |
Oct 13, 2026 19d ago | 6-K | $3.85 $3.85 | · 0.00% | ▼ −1.08% | $5.04 (−30.91%) |
Oct 9, 2026 23d ago | 6-K | $3.75 $3.71 | ▲ +1.07% | ▲ +1.01% | $5.04 (−34.40%) |
Oct 8, 2026 24d ago | 424B4 | $3.75 $3.71 | ▲ +1.07% | ▲ +1.01% | $5.04 (−34.40%) |
Sep 30, 2026 4w ago | EFFECT | $3.12 $3.02 | ▼ −3.21% | ▼ −3.38% | $5.04 (+61.54%) |
Sep 2, 2026 8w ago | 6-K | $4.94 $4.78 | ▼ −3.24% | ▼ −4.29% | $5.04 (+2.02%) |
Aug 10, 2026 11w ago | 6-K | $4.90 $4.99 | ▼ −1.84% | ▼ −2.16% | $5.04 (−2.86%) |
Jul 10, 2026 16w ago | 6-K | $6.61 $6.14 | ▼ −7.04% | ▼ −6.27% | $5.04 (−23.69%) |
Jun 10, 2026 20w ago | 6-K | $0.5869 $0.5783 | ▼ −1.47% | ▼ −3.17% | $5.04 (+758.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers